Our strength in pharmaceutical development and discovery is built on a deep understanding of the biology of central mediators and internal pathways. Our founding focus on fibrosis allowed us to establish expertise in the area of collagen prolyl 4-hydroxylase enzymes, recombinant collagen synthesis, and extracellular matrix-associated processes and pathologies.
Our proprietary programs directly result from our investment into scientific exploration of these critical targets and pathways. Our hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) platform builds off of the discovery that a family of prolyl hydroxylase enzymes is involved in regulation of HIF and HIF-mediated pathways. This insight has allowed us to investigate the ability of roxadustat and other proprietary compounds to therapeutically harness the body’s own natural responses. Through our pamrevlumab platform, we are advancing therapeutic applications that target connective tissue growth factor (CTGF), a central mediator of fibrotic and proliferative disease, as a regulator of extracellular matrix production. We are also evaluating use of FG-5200, a biosynthetic cornea manufactured from proprietary recombinant human collagen, in the treatment of corneal blindness.